Antagonism of the effect of delta sleep-inducing peptide by naloxone in the rat.
Young. A M AM; Key. B J BJ
Key Findings
- DSIP increased total sleep time (both REM and non‑REM) in rats when given intracerebroventricularly.
- The sleep‑enhancing effect was blocked by naloxone, an antagonist selective for mu‑opioid receptors.
Practical Outcomes
- The results suggest DSIP’s sleep‑promoting action may involve opioid pathways, but the delivery method (direct brain injection) and the need for opioid antagonism make it impractical for self‑experimentation. For biohackers, the study offers mechanistic insight rather than a usable protocol.
Summary
In rats, injecting delta sleep‑inducing peptide (DSIP) into the brain boosted both deep and REM sleep, but this effect disappeared when the opioid blocker naloxone was given first, hinting that DSIP works through opioid receptors.
Abstract
The somnogenic properties of delta sleep-inducing peptide (DSIP) were investigated using electroencephalographic criteria. The peptide caused a significant increase in both REM and non-REM sleep at the expense of waking when injected into the lateral ventricle of the rat brain in four doses of 5 micrograms during the dark (waking) phase of the light/dark cycle. Furthermore this sleep promoting effect was blocked by pre-treatment with the opiate antagonist naloxone at a dose level (0.1 mg/Kg s.c.) considered selective for mu-receptors.
Study Information
pubmed
1984
1984-11-01T00:00:00.000Z
10.1016/0028-3908(84)90058-3
15
7